+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Corporate Reputation of Pharma in 2022 - The Patient Perspective - Global Edition

  • Report

  • 138 Pages
  • April 2023
  • Region: Global
  • PatientView
  • ID: 5328622

What 2000+ Patient Groups Say About Pharma in 2022

The ‘Corporate Reputation of Pharma’ survey is now in its 12th year. Between November 2022-February 2023, the survey collected the opinions of 2,207 patient groups on the performance of the pharmaceutical industry during 2022. 

Patient groups responding to 2022's ‘Corporate Reputation of Pharma’ survey are uniquely positioned to comment on the pharma industry, and individual pharma companies, as they understand the experiences of patients, and they also network with all other stakeholders in the healthcare system.

Industry wide
Concerns about Covid-19 receded worldwide during 2022, but the increased positivity towards the pharmaceutical industry encouraged in 2020 and 2021 by the pandemic remained unchanged in 2022. Patient groups around the world still saw pharma as the most-highly regarded among healthcare’s stakeholders during 2022. Pharma also continued to improve its record (and has been doing so since 2018) at carrying out activities of importance to patients - notably, pharma's relationships with patient groups. 

Despite these achievements, just 32% of the Numbers in brackets are the number of respondent patients 2022's respondent patient groups thought groups pharma “Excellent” or “Good” at improving patient access to medicines [a new measure introduced to the ‘Corporate Reputation’ Africa (19 surveys for 2022]. With pandemic-related - issues no longer prominent in most countries in 2022 more long-lasting health concerns - particularly, delays facing patients wishing to receive treatment - returned to the fore again. Worldwide as many as 52% of respondent patient groups felt that pharma was only "Fair or Poor" at improving patient access to medicines. The problem of access was felt especially in Africa (and respondent African patient groups saw unfair pricing as merely one reason among many for this).

Individual companies
The 42 companies assessed in this survey were selected on the following criteria: size of revenue or on request by Companies or patient groups

  • AbbVie
  • Amgen 
  • Astellas Pharma 
  • AstraZeneca 
  • Bayer 
  • Biogen 
  • Biomarin 
  • Boehringer Ingelheim 
  • Bristol Myers Squibb 
  • Chiesi Farmaceutici 
  • CSL Behring 
  • Darichisankyo Sankyo 
  • Eisal 
  • Eli Lilly 
  • Ferring 
  • Gilead Sciences 
  • Grifols 
  • Grunenthal 
  • GSK 
  • Horizon Therapeutics 
  • lpsen 
  • Janssen 
  • LEO Pharma 
  • Lundbeck 
  • Menarini 
  • Merck & Co 
  • Merck KGaA 
  • Novartis 
  • Novo Nordisk 
  • Octapharma 
  • Otsuka 
  • Pfizer 
  • Pierre Fabre 
  • PTC Therapeutics 
  • Roche 
  • Sanofi 
  • Sarepta Therapeutics 
  • Servier 
  • Takeda 
  • UCB 
  • Vertex 
  • ViiV Healthcare 

88% of 2022's 2,207 respondent patient groups stated that they work directly with pharma - The companies rising the most in the upper part of the rankings (out of all 42 companies), 2022 v. suggesting that patient GFOUPS and pharma alike 2021, as assessed by respondent patient groups accept pharma/patient-group relationships as working with the company normal and acceptable trend in healthcare.

Who Should Read this Report? 

Customer Types (Organisations)

  • Pharma companies
  • Biopharma companies
    • Regulatory authorities (e.g EMA, FDA) 
    • NGOs and health charities (usually FOC) including Patient Groups
    • Research and academia

Job Titles/Functions for Pharma and Biopharma Organisations

Core: 

  • Patient Relations
  • Corporate Reputation
  • Public Affairs
  • Professional Affairs
  • Patient Advocacy
  • Communications
  • Market Research

Secondary: 

  • R&D
  • Health economics
  • Outcomes Research
  • Medical Affairs
  • Marketing
  • Brand teams
  • Market Access 
  • Regulatory

Table of Contents

  • Executive Summary
  • Rankings of 42 pharma companies, 2022 v. 2021, as assessed by respondent 42 patient groups familiar with the companies
  • Rankings of 42 pharma companies, 2022 v. 2021, as assessed by respondent 19 patient groups working with the companies
  • Rankings of 15 ‘big-pharma’ companies, 2022 v. 2021, as assessed by AG respondent patient groups familiar with the companies
  • Rankings of 15 ‘big-pharma’ companies, 2022 v. 2021, as assessed by 49 respondent patient groups working with the companies
  • Profiles of the 42 companies, 2022 (v. 2021) 

Appendices
I. Profiles of respondent patient groups, 2022
II. List of respondent patient groups willing to be attributed, 2022
What nine pharmaceutical companies say about their patient-oriented activities, 2022/2023 (published as a separate supplement)

Tables and Charts

  • The ten indicators measuring corporate reputation, 2022 
  • Respondent patient groups, 2022: familiarity, and partnerships, with pharma 
  • The types of relationships that respondent patient groups have with pharma companies, 2022
  • The corporate reputation of the pharmaceutical industry over time, 2018-2022, according to respondent patient groups
  • The corporate reputation of the pharma industry, compared with that of other 
  • healthcare sectors, 2022 v. 2021, according to respondent patient groups
  • How good or bad the pharma industry was at carrying out specific activities, 2022 
  • How good or bad the pharma industry was at carrying out specific activities, 2018-2022
  • The corporate reputation of the pharma industry, 2022 - from the perspective of respondent patient groups based in different regions of the world
  • Companies rising the most in the rankings, 2022 v.2021, as assessed by respondent patient groups familiar, and working, with the company
  • Rankings of 42 pharma companies, 2022 v. 2021, as assessed by respondent patient groups familiar with the companies
  • Rankings of 42 pharma companies, 2022 v. 2021, as assessed by respondent patient groups working with the companies
  • Rankings of 15 ‘big-pharma companies, 2022 v. 2021, as assessed by AG respondent patient groups familiar with the companies
  • Rankings of 15 ‘big-pharma companies, 2021 v. 2020, as assessed by ie respondent patient groups working with the companies
  • Profiles of the 42 companies, 2022 (v. 2021) 

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie
  • Amgen 
  • Astellas Pharma 
  • AstraZeneca 
  • Bayer 
  • Biogen 
  • Biomarin 
  • Boehringer Ingelheim 
  • Bristol Myers Squibb 
  • Chiesi Farmaceutici 
  • CSL Behring 
  • Darichisankyo Sankyo 
  • Eisal 
  • Eli Lilly 
  • Ferring 
  • Gilead Sciences 
  • Grifols 
  • Grunenthal 
  • GSK 
  • Horizon Therapeutics 
  • lpsen 
  • Janssen 
  • LEO Pharma 
  • Lundbeck 
  • Menarini 
  • Merck & Co 
  • Merck KGaA 
  • Novartis 
  • Novo Nordisk 
  • Octapharma 
  • Otsuka 
  • Pfizer 
  • Pierre Fabre 
  • PTC Therapeutics 
  • Roche 
  • Sanofi 
  • Sarepta Therapeutics 
  • Servier 
  • Takeda 
  • UCB 
  • Vertex 
  • ViiV Healthcare